ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Pharmacovigilance Coordinator at Cogent Biosciences - ApplyBlast

Pharmacovigilance Coordinator

Cogent Biosciences

18 days ago

3.8 on Glassdoor

Waltham, Massachusetts, United States

Onsite

Full Time

Junior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Pharmacovigilance Coordinator manages the day-to-day operations of Pharmacovigilance, including monitoring the PV inbox, tracking vendor safety deliverables, and supporting commercial safety data reconciliations. This hands-on role requires an organized individual to maintain the PV deliverable calendar, oversee case tracking, and ensure compliance with regulatory timelines. The position involves coordinating meetings, maintaining inspection-ready records, and supporting audit readiness within a growing team.

Responsibilities

Monitor and triage the shared PV mailbox daily to route safety information
Track individual case safety reports through the vendor's case processing workflow
Support periodic reconciliations of adverse events across commercial sources

Skills

About Cogent Biosciences

cogentbio.com

Headquarters

Waltham, Massachusetts, United States

Company Size

51-200 employees

Founded

2014

View Profile

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, including cancers, autoimmune conditions, and rare diseases. The company leverages validated biology to design best-in-class small molecule therapeutics, with its lead program bezuclastinib targeting conditions such as Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST). Cogent operates discovery and development offices in Boulder, Colorado and Waltham, Massachusetts, and is actively advancing clinical-stage programs including a Phase 3 trial and an FDA-accepted NDA for bezuclastinib.